First Complete Response in Concurrent BTKi azer-cel Cohort
Open PDF
| Stock | Imugene Ltd (IMU.ASX) |
|---|---|
| Release Time | 30 Jun 2026, 11:45 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imugene Reports First Complete Response in BTKi Cohort
Key Points
- First patient in BTKi cohort achieved complete response
- Patient had previously failed BTKi therapy
- BTKi therapy addresses a $12.0 billion global market
Full Summary
Imugene Limited (ASX: IMU) reports the first complete response in the concurrent BTKi cohort of its ongoing azer-cel Phase 1b trial. The patient, a Follicular Lymphoma (FL) patient who had previously failed BTKi therapy, achieved a complete response at the Day 28 assessment. This cohort evaluates whether concurrent dosing of azer-cel with a BTKi may restore or enhance therapeutic activity in patients who have relapsed on or are refractory to BTKi therapy. The global BTKi market reached approximately US$12.0 billion in 2025. The trial is ongoing across ten US and five Australian sites.
Outlook
Imugene believes this combination approach could represent a meaningful development pathway for azer-cel.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In